TFE3 and renal cell carcinoma: Activity of tyrosine kinase inhibitors (TKI) against TFE3-RCC has recently been reported in in vitro organoid-based experiments [9], and a clinically complete response to the multi-targeted TKI sunitinib was reported in a child with metastatic TFE3 translocation RCC [10].